Stock Ratings / Health Care / BEAM / financials

DNLI (40) ADMA (67) RXRX (43) TARS (46) ⌘ Pro Terminal →

Beam Therapeutics Inc. (BEAM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$28.84 +0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.80

Beam Therapeutics Inc. (BEAM) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $2.98B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $28.80 (-0.15%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BEAM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY BEAM SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 6.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$25.70-8.7% Next Q

Q2 (-2Q)

Grade E$23.47+2.5% Next Q

Q3 (-1Q)

Grade D$24.05+19.9% Next Q

Current

Grade D-$28.84-6.7% Hist 90D α

Trajectory: E (35) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BEAM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BEAM currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.93) and Max Pain ($30.28) forces dealer call-delta covering toward $40.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BEAM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BEAM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BEAM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $377.7M

FY24

Rev $63.5M

FY25

Rev $139.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$139.7M	52%	-80%	-$80.0M	-$360.0M	-32.1%
FY 2024	$63.5M	52%	-80%	-$376.7M	-$356.2M	-45%
FY 2023	$377.7M	52%	-46.7%	-$132.5M	-$149.2M	-32.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BEAM)

✓Walkthrough of BEAM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BEAM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.91%▲ RESISTANCE BREAKOUT

2026-10-30O $28.27H $28.85L $26.43C $28.84VOL 1.50M

RES: $24.12SUP: $20.84SMA50: $25.93SMA200: $28.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BEAM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BEAM Butterfly Map → + Track BEAM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +120.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BEAM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BEAM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BEAM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BEAM)

Health Care Rank #536 of 1016 ⚔️ DNLI vs BEAM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BEAM vs. DNLI, ADMA, RXRX, TARS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Beam Therapeutics Inc. (BEAM) ranks #536 by composite RQD confidence (43/100, grade D-) and #208 by equity capitalization ($2.98B). Within this direct 5-issuer industry benchmark cohort, ADMA leads on earnings valuation at 17.9x trailing P/E, while ADMA leads on capital efficiency and profitability with 32.9% ROIC and 57.4% gross margin. ADMA currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with BEAM at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BEAM ACTIVE Beam Therapeutics Inc.	D-	43/100	—	—	-32.1%	+0.21%	$2.98B	Benchmark Subject
DNLI Denali Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.16%	$3.09B	/dnli-vs-beam →
ADMA ADMA Biologics Inc	C+	67/100	17.9x	57.4%	32.9%	+4.17%	$2.63B	/adma-vs-beam →
RXRX Recursion Pharmaceuticals Inc.	D-	43/100	—	5.0%	-35.0%	-2.53%	$2.53B	/rxrx-vs-beam →
TARS Tarsus Pharmaceuticals Inc.	D	46/100	—	—	-24.1%	+2.98%	$3.66B	/tars-vs-beam →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001745999

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Beam Therapeutics Inc. (BEAM) reported GAAP revenue of $139.7M (+120.0% vs. FY2024 revenue of $63.5M , and -63.0% cumulative change since FY2023) , GAAP net income of -$80.0M, operating cash flow of -$345.1M, and free cash flow of -$360.0M (-1.1% YoY). On the balance sheet, BEAM closed FY2025 with $1.48B in total assets against $0 in total debt (Altman Z-Score: 6.00, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$139.7M	-$80.0M	-$345.1M	-$360.0M	$1.48B	—
FY2024 (FY)	2024-12-31	$63.5M	-$376.7M	-$347.2M	-$356.2M	$1.10B	—
FY2023 (FY)	2023-12-31	$377.7M	-$132.5M	-$149.2M	-$149.2M	—	—

3. BEAM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BEAM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Beam Therapeutics Inc. (NASDAQ: BEAM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $28.84 (+0.21% 1D, market cap $2.98B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BEAM ranks #536 in composite RQD confidence.

How does BEAM compare to DNLI and ADMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BEAM carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, DNLI (Denali Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.09B) and ADMA (ADMA Biologics Inc) posts a C+ grade (67/100 RQD, P/E 17.9x, ROIC 32.9%, cap $2.63B). Among the 5-stock peer group, ADMA leads on earnings multiple (17.9x) while ADMA leads on capital efficiency (32.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BEAM?

Per BEAM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001745999), Beam Therapeutics Inc. generated $139.7M in revenue (+120.0% YoY), -$80.0M in net income, and -$360.0M in free cash flow against $1.48B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BEAM trading relative to its 50-day, 200-day, and 52-week technical levels?

BEAM last traded at $28.84 (+0.21% on volume of 2,001,003 shares), positioning the stock +11.22% above its 50-day simple moving average ($25.93) and +2.49% above its 200-day simple moving average ($28.14). Across its 52-week range of $20.23 to $38.26, BEAM sits at the 47.8% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.24 to $32.44).

BEAM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Beam Therapeutics Inc. (BEAM)?

In FY 2025 (10-K), BEAM converted $139.7M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: BEAM RQD Cockpit BEAM 12M Forecast BEAM Earnings & Move BEAM Dividends & DRIP BEAM Insiders & 13F BEAM Whale Options BEAM Profit Sankey BEAM News & Why